OctoPlus signs drug delivery agreement with Novartis

Published: 1-Jul-2010

PolyActive technology to be used to develop controlled release formulation of undisclosed compound


OctoPlus, a Dutch drug delivery company, has signed an agreement with Novartis relating to the use of OctoPlus' controlled release technology.

Under the contract, OctoPlus will develop, up to in vivo feasibility, a controlled release formulation of an undisclosed compound using its PolyActive proprietary drug delivery technology. Novartis will fully reimburse OctoPlus for its activities under the agreement. Further financial terms of the agreement were not disclosed.

Simon Sturge, ceo of OctoPlus, said: ‘I am delighted to see our technology being evaluated by such a prestigious company as Novartis. This along with the recent data on Locteron in more than 175 patients continues to build the strong support behind our PolyActive controlled release technology and our capabilities in this area.’

You may also like